• Hironori Koga, Satoshi Hagiwara, Masafumi Inomata, Jyunya Kusaka, Nobuhiko Asai, Masayoshi Oyama, Kanako Kita, Kenji Kashima, Isao Yokoi, and Takayuki Noguchi.
• Department of Anesthesiology and Intensive Care Medicine, Oita University Faculty of Medicine, Oita, Japan.
• J. Surg. Res. 2012 Jun 1; 175 (1): 118-22.

BackgroundIschemic liver injury is often the result of surgical procedures such as liver transplantation and hepatic resection. Liver damage occurs after reperfusion, leading to increased systemic inflammation. Recent studies have reported that vitamin E and glutathione can ameliorate ischemia-reperfusion (I/R) injury. In the present study, we evaluated the ability of a new vitamin E derivative, ETS-GS, to improve liver I/R injury.Materials And MethodsMale Wistar received a subcutaneous injection of ETS-GS (10 mg/kg) or saline before experimentally-induced liver I/R injury or sham treatment. The rats were sacrificed after the 60-min ischemia and 24-h reperfusion. Histology and serum levels of cytokines [tumor necrosis factor (TNF)-α, interleukin (IL)-6, and high-mobility group box 1 (HMGB1) protein] and liver enzymes were determined to evaluate the protective effects of ETS-GS.ResultsWe found that ETS-GS treatment attenuated I/R-induced histologic alterations, reduced levels of liver enzymes aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH). In addition, ETS-GS treatment decreased serum cytokine levels.ConclusionsTaken together, our results demonstrate that ETS-GS attenuates I/R injury in a rat model and suggests that ETS-GS may exert anti-inflammatory effects. Accordingly, ETS-GS may have therapeutic potential to treat various clinical conditions involving I/R injury.Copyright © 2012 Elsevier Inc. All rights reserved.

21 keywords...

hide…